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Purpose  Acute kidney injury (AKI) is a common and serious adverse effect of 2 
cisplatin-based chemotherapy.  However, traditional markers of kidney function, such 3 
as serum creatinine, are suboptimal, because they are not sensitive measures of proximal 4 
tubular injury.  We aimed to determine whether the new urinary biomarkers such as 5 
kidney injury molecule-1 (KIM-1), monocyte chemotactic protein-1 (MCP-1), and 6 
neutrophil gelatinase-associated lipocalin (NGAL) could detect cisplatin-induced AKI 7 
in lung cancer patients in comparison with the conventional urinary proteins such as 8 
N-acetyl-β-D-glucosaminidase (NAG) and β2-microglobulin. 9 
Methods  We measured KIM-1, MCP-1, NGAL, NAG and β2-microglobulin 10 
concentrations in urine samples from 11 lung cancer patients, which were collected the 11 
day before cisplatin administration and on days 3, 7, and 14. Subsequently, we 12 
evaluated these biomarkers by comparing their concentrations in 30 AKI positive (+) 13 
and 12 AKI negative (−) samples and performing receiver operating characteristic 14 
(ROC) curve analyses.  15 
Results  The urinary levels normalized with urine creatinine of KIM-1 and MCP-1, but 16 
not NGAL, NAG and β2-microglobulin in AKI (+) samples were significantly higher 17 
than those in AKI (−) samples.  In addition, ROC curve analyses revealed that KIM-1 18 
and MCP-1, but not NGAL, could detect AKI with high accuracy (area under the curve 19 
[AUC] = 0.858, 0.850, and 0.608, respectively).  The combination of KIM-1 and 20 
MCP-1 outperformed either biomarker alone (AUC = 0.871). 21 
Conclusions  Urinary KIM-1 and MCP-1, either alone or in combination, may 22 
represent biomarkers of cisplatin-induced AKI in lung cancer patients.  23 
 24 
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 Cisplatin is a widely used anticancer drug for several types of solid tumors, 2 
such as bladder, cervical, head and neck, esophageal, and lung cancers [1].  However, 3 
nephrotoxicity, which is a dose-limiting adverse effect, is a serious problem.  About 4 
20% of patients treated with high doses of cisplatin have peak serum creatinine (Scr) 5 
levels greater than 2.0 mg/dL, which are associated with mortality rates of 30% or more 6 
[2, 3].  Although this toxicity is transient in most patients and can be mitigated by 7 
other treatments, such as prehydration or concomitant osmotic diuresis [2], long-term 8 
treatment with cisplatin requires careful monitoring of kidney function. 9 
 In November 2010, the standard dosage of cisplatin for lung cancer treatment 10 
in Kyoto University Hospital was increased from 60 to 80 mg/m2.  This is of concern 11 
not only due to the dose-dependent nephrotoxicity of cisplatin but also because our 12 
previous research on a rat model of acute kidney injury (AKI) showed that proximal 13 
tubular injuries are not always associated with significant changes in the Scr levels [4].  14 
Although renal biopsy is the gold standard for diagnosing AKI, not all cancer patients 15 
treated with cisplatin can undergo this procedure.  Therefore, there is a need for 16 
noninvasive biomarkers of cisplatin-induced AKI.   17 
 Traditional serum markers of kidney function, such as Scr and blood urea 18 
nitrogen (BUN), are suboptimal because they only reflect changes in the glomerular 19 
filtration rate [3], which is a nonspecific measure of proximal tubular injury that is 20 
usually apparent only after significant kidney damage [5].  As a result, serum 21 
biomarkers of kidney function may not be adequate to accurately detect AKI.  Other 22 
noninvasive urinary biomarkers, such as kidney injury molecule-1 (KIM-1) [6, 7] and 23 





of proximal tubular injury or AKI.  KIM-1 is a type-1 cell membrane glycoprotein 1 
up-regulated in dedifferentiated proximal tubule epithelial cells [10].  Its ectodomain 2 
was shed and could be quantitated in the urine following kidney injury in a rodent 3 
model of cisplatin-induced AKI [6].  On the other hand, NGAL expression is induced 4 
in epithelial cells upon inflammation or malignancy.  The expression of NGAL has 5 
been shown to be up-regulated in the kidney proximal tubule cells and urine in a murine 6 
model following ischemic or cisplatin-induced AKI [11].  In addition, recently we 7 
showed that the monocyte chemotactic protein-1 (MCP-1) levels are significantly 8 
increased in proximal tubular epithelial cells and urine following cisplatin-induced AKI 9 
in rats [12].  MCP-1 is a proinflammatory chemokine that plays a role in the 10 
recruitment of monocytes to the sites of injury and infection.  Similar to NGAL, its 11 
expression levels are also up-regulated in the kidney proximal tubule cells following 12 
ischemic injury [13].  Therefore, we here investigated whether KIM-1, NGAL, and 13 
MCP-1, either individually or in combination, can detect cisplatin-induced 14 
nephrotoxicity in lung cancer patients in comparison with two conventional urinary 15 
proteins N-acetyl-β-D-glucosaminidase (NAG) and β2-microglobulin. 16 





MATERIALS AND METHODS 1 
Patients and study design 2 
We enrolled 11 primary lung cancer patients treated with cisplatin-based 3 
chemotherapy at Kyoto University Hospital between June 2011 and June 2012.  The 4 
administration schedules of chemotherapy and supportive therapy are shown in Figure 1.  5 
None of the patients received magnesium supplementation. 6 
This study was conducted in accordance with the Declaration of Helsinki and 7 
was approved by the Kyoto University Graduate School and Faculty of Medicine Ethics 8 
Committee.  All patients provided written informed consent. 9 
 10 
Data collection and diagnostic criteria for acute kidney injury 11 
Clinical information, treatments, and laboratory data were obtained from the 12 
patients’ electronic medical records.  Considering that extensive continuous hydration 13 
(3000 mL/24 h) is provided with the administration of cisplatin, cisplatin-induced renal 14 
impairment was diagnosed in patients with an increase in the BUN level of more than 15 
20 mg/dL and/or the Scr level of 50% in comparison with the baseline.  Patients whose 16 
BUN level at the administration of cisplatin was higher than 20 mg/dL were excluded.  17 
Urine samples were classified as either AKI positive (+) or negative (−).  18 
 19 
Urine collection and biomarker analysis 20 
We collected urine samples on the day before cisplatin administration (day 0) 21 
and subsequently, on days 3, 7, and 14.  Urine samples were collected into tubes with 22 






We measured the KIM-1 concentrations using Luminex xMAP microspheres 1 
with polyclonal antibodies raised against the ectodomain of human KIM-1, as described 2 
previously [14].  To measure the MCP-1 and NGAL concentrations, we used the 3 
Human CCL2/MCP-1 DuoSet and Human Lipocalin-2/NGAL DuoSet enzyme-linked 4 
immunosorbent assay kits (R&D Systems Inc., Minneapolis, MN), respectively, 5 
according to the manufacturer’s instructions.  Briefly, a 96-well microplate was coated 6 
with capture antibodies, and then blocked with 1% bovine serum albumin in 7 
phosphate-buffered saline.  Subsequently, 100-µL samples were incubated in the 8 
blocked wells for two hours, followed by incubation with biotinylated detection 9 
antibodies for two hours and streptavidin-conjugated horseradish peroxidase (HRP) for 10 
20 minutes at room temperature.  Finally, MCP-1 and NGAL were detected by adding 11 
HRP substrate and measuring the optical density at 450 nm. 12 
The concentrations of NAG and β2-microglobulin, which are tubular injury 13 
markers, were measured by using commercial kits: the NAG test Shionogi (Shionogi 14 
Co., Osaka, Japan) and beta-2 Microglobulin Human SimpleStep ELISA™ Kit (Abcam, 15 
Cambridge, UK), according to the manufacturers’ instructions. 16 
The levels of all biomarkers were normalized to the urinary creatinine 17 
concentration, which was measured by using an assay kit (LabAssayTM Creatinine; 18 
Wako Pure Chemical Industries, Osaka, Japan).  19 
 20 
Statistical analyses 21 
To evaluate the diagnostic accuracy of KIM-1, MCP-1, and NGAL, we 22 
calculated the area under the receiver operating characteristic (AUC-ROC) curve using 23 





Mann-Whitney U test, and p-values less than 0.05 were considered statistically 1 
significant.  These analyses were performed using Prism Version 5.0 (GraphPad, San 2 






Patient characteristics 2 
The patient characteristics are shown in Table 1.  The mean (standard 3 
deviation [SD]) age of the patients in this study was 65.9 (10.1) years (range: 49–77 4 
years).  All patients had stage III lung cancer.  The baseline mean (SD) levels of Scr 5 
and BUN were 0.75 (0.26) mg/dL and 14.3 (3.9) mg/dL, respectively.  Seven patients 6 
were treated with 80 mg/m2 cisplatin, while the remaining patients were administered 7 
lower doses due to reduced kidney function.  The mean total cisplatin dosage was 8 
108.1 (20.1) mg.  Ten out of the 11 patients received cisplatin combined with 9 
vinorelbine (VNR).   10 
 11 
Urinary and serum biomarkers of kidney function exhibit time-dependent changes 12 
during cisplatin-induced acute kidney injury 13 
Surprisingly, all but one patient met the diagnostic criteria for AKI throughout 14 
the study.  We observed time-dependent changes in the levels of serum and urinary 15 
biomarkers during cisplatin treatment.  Figure 2 shows an example of these changes in 16 
a 49-year-old male patient with stage IIIA non-small cell lung adenocarcinoma treated 17 
with a combination of vinorelbine (20 mg/m2, 31 mg/body), cisplatin (80 mg/m2, 125 18 
mg/body), and radiation.  On day 3 after cisplatin treatment, AKI was diagnosed, 19 
because the BUN level exceeded 20 mg/dL.  Between the cisplatin treatment initiation 20 
(day 0) and day 7, the Scr and BUN (Figure 2a) and urinary KIM-1 and MCP-1 levels 21 







Urinary levels of kidney injury molecule-1 or monocyte chemotactic protein-1 can 1 
detect cisplatin-induced acute kidney injury 2 
To determine whether the urinary levels of KIM-1, MCP-1, and NGAL can be 3 
used to detect cisplatin-induced AKI, we compared the levels of these biomarkers in 30 4 
AKI (+) and 12 AKI ( − ) urine samples.  First, we compared the absolute 5 
concentrations of urinary KIM-1, MCP-1 and NGAL, as shown in SF1.  The 6 
concentrations of KIM-1 were significantly higher in AKI (+) samples than in AKI (−) 7 
samples (p < 0.01), while the MCP-1 and NGAL concentrations in the urine did not 8 
differ between the two groups.  Next, to consider the inter-individual differences of 9 
urine samples, the concentrations of these markers normalized to urinary creatinine 10 
concentration were compared between AKI (−) samples and AKI (+) samples (Figure 3).  11 
The urinary KIM-1 and MCP-1 levels in AKI (+) samples were significantly higher than 12 
in AKI (−) samples (p < 0.01; Figures 3a, b).  However, the NGAL concentrations did 13 
not significantly differ between AKI (+) and AKI (−) samples (Figure 3c).  These 14 
results suggested that the urinary levels of KIM-1 or MCP-1 could detect 15 
cisplatin-induced AKI.  In addition, we measured the urinary concentrations of NAG 16 
and β2-microglobulin, as tubular toxicity markers (SF1d, e and Figures 3d, e).  There 17 
were no significant differences observed between the two groups, with or without 18 
normalization to the urinary creatinine concentrations. 19 
Further, we compared the Scr levels to the concentrations of KIM-1, MCP-1 20 
and NGAL (SF2).  However, there was no correlation between the Scr level and any of 21 
the urinary biomarkers.  22 
 23 





To confirm the above findings, we performed ROC curve analyses (Figure 4).  1 
The AUC-ROCs of KIM-1, MCP-1, and NGAL were 0.858 (p < 0.01), 0.850 (p < 0.01), 2 
and 0.608 (p > 0.05), respectively (Table 2), supporting the conclusion that urinary 3 
KIM-1 or MCP-1 can accurately detect cisplatin-induced AKI in lung cancer patients.  4 
In addition, the cut-off values of KIM-1, MCP-1, and NGAL were 2.45, 0.26, and 17.2 5 
ng/mg creatinine, respectively (Table 2).   6 
 7 
Combination of kidney injury molecule-1 and monocyte chemotactic protein-1 8 
enhances detection of cisplatin-induced acute kidney injury 9 
 Since a combination of two biomarkers may be better than a single biomarker, 10 
we tested whether a combination of KIM-1 and MCP-1 can detect cisplatin-induced 11 
AKI better than either biomarker alone.  We defined the combination biomarker as 12 
follows: 13 (𝐾𝐾𝐾𝐾𝐾𝐾– 1)𝐼𝐼(𝐾𝐾𝐾𝐾𝐾𝐾– 1)𝑐𝑐𝑐𝑐𝑐𝑐−𝑜𝑜𝑜𝑜𝑜𝑜 + (𝐾𝐾𝑀𝑀𝑀𝑀– 1)𝑖𝑖(𝐾𝐾𝑀𝑀𝑀𝑀– 1)𝑐𝑐𝑐𝑐𝑐𝑐−𝑜𝑜𝑜𝑜𝑜𝑜 14 
In this equation, the KIM-1 and MCP-1 concentrations (denoted by i) are normalized to 15 
their ROC cut-off values.  The AUC-ROC for this combination, 0.871, was higher than 16 







  2 
In this study, we examined whether KIM-1, NGAL, and MCP-1 can detect 3 
cisplatin-induced AKI in lung cancer patients.  Our results suggested that KIM-1 and 4 
MCP-1, but not NGAL as well as NAG and β2-microglobulin, can discriminate 5 
between AKI (+) and AKI (−) urine samples.  The potential usefulness of KIM-1 is 6 
consistent with a previous report that urinary KIM-1 is a sensitive and accurate 7 
biomarker of cisplatin-induced AKI in both preclinical and clinical settings [15].  8 
Recently, Tekce et al. [16] also reported that urinary KIM-1 concentrations on the first 9 
day after treatment may predict cisplatin-induced AKI with high sensitivity and 10 
specificity in the clinical setting.  Although there have not been any studies using 11 
MCP-1 as a biomarker of cisplatin-induced AKI, our previous findings that 12 
cisplatin-induced nephrotoxicity increases urinary MCP-1 in rats [12] also support this 13 
conclusion.  Further, although the concentrations of these markers did not correlate 14 
with the Scr levels, our results indicate the possibility that these new urinary biomarkers 15 
are more sensitive and specific than Scr for cisplatin-induced AKI. 16 
However, our NGAL findings contradict recent reports that it may be an early 17 
biomarker of AKI in cancer patients treated with cisplatin-based chemotherapy [17-19].  18 
There are two possible reasons for this discrepancy.  First, the NGAL levels may have 19 
differed among studies because urine samples are collected and analyzed at different 20 
time points.  For example, Lin et al. [18] analyzed urine samples between four hours 21 
and four days after cisplatin infusion and found that urinary NGAL levels significantly 22 
increased between 12 hours and three days later in AKI (+) samples compared with the 23 
baseline levels.  In contrast, we measured NGAL concentrations at later time points 24 





(−) samples.  In our study, analyzing urine samples at earlier time points was not 1 
possible because the patients were prehydrated, so their urine would have been too 2 
diluted during the first two or three days after cisplatin administration.  Second, the 3 
NGAL levels may differ among the studies due to differences in the diagnostic criteria 4 
for AKI.  Many investigators diagnose AKI using the Risk, Injury, Failure, Loss of 5 
kidney function and End-stage kidney disease or Acute Kidney Injury Network 6 
classifications, which are based on changes in the Scr levels and urine output.  In our 7 
study, we used expedient criteria slightly modified from the KDIGO (Kidney Disease: 8 
Improving Guideline Outcomes) criteria; if the level of Scr was increased more than 9 
1.5-fold compared to the baseline and/or that of BUN was over than 20 mg/dL after the 10 
administration of cisplatin, the sample was classified as AKI (+).  There are two 11 
reasons for why we used the modified KDIGO criteria in this study.  First, because the 12 
urine outputs of our patients were too high due to the prehydration, we could not 13 
accurately diagnose AKI based on the urine output.  Second, because the Scr levels are 14 
influenced by the muscle mass, it is inadequate to monitor the kidney function based on 15 
only the Scr levels, particularly in elderly patients.  Hence, we defined the criteria 16 
based on the levels of both Scr and BUN.  However, further research is needed to 17 
determine more specific diagnostic criteria for cisplatin-induced AKI.   18 
Finally, our finding that the AUC-ROC of the combination of KIM-1 and 19 
MCP-1 is higher than that of either biomarker alone (Figure 4d) is consistent with 20 
previous reports that a combination of two biomarkers may have better diagnostic 21 
performance than a single biomarker [20, 21].  However, unlike these previous studies, 22 
which used a logistic regression model to combine two biomarkers, we simply summed 23 





this would be easier to calculate in the clinical setting.  Although a dipstick assay for 1 
KIM-1 has recently become available [15], there is no similar assay for measuring 2 
MCP-1 levels quickly and accurately; such an assays could enable early detection and 3 
improved treatment of cisplatin-induced AKI.   4 
In conclusion, we here showed that urinary KIM-1 and MCP-1, either alone or 5 
in combination, may represent accurate biomarkers of cisplatin-induced AKI in lung 6 
cancer patients.  These findings may also facilitate the development of new methods to 7 
monitor kidney function.  However, because of the small number of patients in the 8 
present study, larger studies are required in the future to confirm our findings. 9 
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Table 1. Patient characteristics 2 
Characteristic n 
Number of patients 11 
Age, mean (SD) (years) 65.9 (10.1) (range: 49–77) 
Sex (male/female) 7/4 
BSA, mean (SD) (m2) 1.48 (0.19) (range: 1.17-1.72) 
Baseline Scr, mean (SD) (mg/dL) 0.75 (0.26) (range: 0.3–1.3) 
Baseline BUN, mean (SD) (mg/dL) 14.3 (3.9) (range: 8–19) 
Type of lung cancer  
 Small-cell 1 
 Adenocarcinoma 5 
 Squamous cell carcinoma 5 
Tumor stage  
 IIIA 8 
 IIIB 3 
Cisplatin dosage  
 80 mg/m2 7 
 64 mg/m2 1 
 60 mg/m2 3 
Total cisplatin dosage, mean (SD) (mg) 108.1 (20.1) (range: 77-131) 
Co-administrated drugs  
 VNR 10 
 ETP 1 
Number of chemotherapy courses  
 First 9 
 Second 2 
Radiation  
 Yes 6 
 No 5 
Abbreviations: SD, standard deviation; BSA, body surface area; Scr, serum creatinine; 3 






Table 2. Receiver operating characteristic curve analyses of kidney function 1 



















Abbreviations: AUC-ROC, area under the receiver operating characteristic curve; CI, 3 
confidence interval; KIM-1, kidney injury molecule-1; MCP-1, monocyte chemotactic 4 
protein-1; NGAL, neutrophil gelatinase-associated lipocalin.  5 
Statistical analyses were performed using the Mann-Whitney U test. **p<0.01. 6 





FIGURE LEGENDS 1 
 2 
Figure 1. Detail schedules of the chemotherapy regimens used. 3 
Detailed administration schedules of each regimen, VNR/CDDP or ETP/CDDP, for our 4 
lung cancer patients are shown.  As the supportive therapy, maintenance fluid (Soldem 5 
3A®) and saline were injected along with antiemetics (palonosetron and dexamethasone 6 
sodium phosphate).  At the first day of chemotherapy, the patients received extensive 7 
continuous infusion of approximately 3,000 mL.  The standard dosages of VNR and 8 
ETP were 25 mg/m2 and 100 mg/m2, respectively.  CDDP, cisplatin; VNR, vinorelbine; 9 
ETP, etoposide. 10 
 11 
Figure 2. Changes in biomarker levels in a representative lung cancer patient with 12 
cisplatin-induced acute kidney injury. 13 
Time-dependent changes in the levels of serum and urinary biomarkers during 14 
cisplatin-based chemotherapy in a 49-year-old male patient with stage IIIA non-small 15 
cell lung adenocarcinoma.  (a) Changes in serum creatinine (Scr; white circle) and 16 
blood urea nitrogen (BUN; black circle).  Since BUN was greater than 20 mg/dL on 17 
day 3, this patient was diagnosed with acute kidney injury (AKI).  (b) Changes in 18 
urinary levels of kidney injury molecule-1 (KIM-1; white circle), neutrophil 19 
gelatinase-associated lipocalin (NGAL; white triangle), and monocyte chemotactic 20 
protein-1 (MCP-1; black circle).   21 
 22 
Figure 3. Differences in urinary levels of kidney function biomarkers in lung 23 





Differences in the urinary levels of kidney injury molecule-1 (KIM-1) (a), monocyte 1 
chemotactic protein-1 (MCP-1) (b), neutrophil gelatinase-associated lipocalin (NGAL) 2 
(c), N-acetyl-β-D-glucosaminidase (NAG) (d), and β2-microglobulin (e) in acute kidney 3 
injury (AKI) positive (+) and AKI negative (−) samples from lung cancer patients 4 
treated with cisplatin.  The biomarker concentrations were normalized to the urinary 5 
creatinine concentration.  Statistical analyses were performed using the Mann-Whitney 6 
U test.  **p < 0.01 vs. AKI (−).  Horizontal bar indicates the median value. 7 
 8 
Figure 4. Receiver operating characteristic curve analyses of urinary biomarkers 9 
of acute kidney injury 10 
Receiver operating characteristic (ROC) curves demonstrating the sensitivity and 11 
specificity of kidney injury molecule-1 (KIM-1) (a), monocyte chemotactic protein-1 12 
(MCP-1) (b), and neutrophil gelatinase-associated lipocalin (NGAL) (c), and the 13 
combination of KIM-1 and MCP-1 (d) with respect to the definition of acute kidney 14 
injury (AKI) by serum creatinine or blood urea nitrogen.  AUC, area under the curve. 15 
 16 
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SF1, Supplementary Figure 1. Differences in the absolute concentrations of urinary biomarkers 
in lung cancer patients with or without acute kidney injury.
Differences in the absolute urinary levels of kidney injury molecule-1 (KIM-1) (a), monocyte 
chemotactic protein-1 (MCP-1) (b), neutrophil gelatinase-associated lipocalin (NGAL) (c), N-acetyl-
β-D-glucosaminidase (NAG) (d), and β2-microglobulin (e) in acute kidney injury (AKI) positive (+) 
and AKI negative (−) samples from lung cancer patients treated with cisplatin.  Statistical analyses 
were performed using the Mann-Whitney U test.  **p < 0.01 vs. AKI (−).  Horizontal bar indicates 
the median value.
SF2, Supplementary Figure 2. Correlations between the serum creatinine levels and urinary 
biomarkers.
No correlation between the serum creatinine (Scr) levels and urinary kidney injury molecule-1 
(KIM-1) (a), monocyte chemotactic protein-1 (MCP-1) (b), or neutrophil gelatinase-associated 
lipocalin (NGAL) (c) was observed.  White circles, acute kidney injury (AKI) (−) samples; gray 
circles, AKI (+) samples. 
